{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:03:09Z","timestamp":1788624189125,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bisphosphonate (BP) discontinuation has been advised as a measure to prevent the incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ), however, its efficacy remains controversial. This study aimed to analyze the efficacy of BP discontinuation in reducing BRONJ severity following tooth extraction in a rat model. Thirty-four male Sprague\u2013Dawley rats were divided into two BRONJ model categories: oral administration (PO) of alendronate (1\u00a0mg\/kg) for 3 and 8\u00a0weeks and intraperitoneal (IP) injection of pamidronate (3\u00a0mg\/kg) and dexamethasone (1\u00a0mg\/kg) for 20\u00a0days. The PO model was divided into five groups (a control group without BPs and four experimental groups with 1-week discontinuation). The IP model was divided into two groups consisting of group I (without discontinuation) and group II (1-week discontinuation). One molar from both sides of the mandible was extracted. After extraction, the PO models were sacrificed at 3 and 5\u00a0weeks, and the IP models were sacrificed either immediately or at 2, 4, 6, and 8\u00a0weeks. Micro-CT showed non-significant differences among PO groups but significant differences were observed between IP groups. Most bone remodeling parameters within group I of the IP model differed significantly (<jats:italic>p-<\/jats:italic>value\u2009&lt;\u20090.05). Histologically, group I showed a significantly higher percentage of necrotic bone than group II (51.93\u2009\u00b1\u200912.75%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and a higher number of detached osteoclasts in TRAP staining. With discontinuation of medication for at least 1\u00a0week in rats, the effects of BPs on alveolar bone are suppressed and bone turnover and osteoclast functions are restored.<\/jats:p>","DOI":"10.1038\/s41598-022-25347-3","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T10:03:32Z","timestamp":1670839412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Significance of medication discontinuation on bisphosphonate-related jaw osteonecrosis in a rat model"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-499X","authenticated-orcid":false,"given":"Kezia Rachellea","family":"Mustakim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-9924","authenticated-orcid":false,"given":"Mi Young","family":"Eo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-980X","authenticated-orcid":false,"given":"Ji Hye","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-767X","authenticated-orcid":false,"given":"Ju Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-8479","authenticated-orcid":false,"given":"Hoon","family":"Myoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-0489","authenticated-orcid":false,"given":"Soung Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"25347_CR1","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1038\/sj.bdj.2013.327","volume":"214","author":"T Taylor","year":"2013","unstructured":"Taylor, T., Bryant, C. & Popat, S. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King\u2019s College Hospital. Br. Dent. J. 214, E18 (2013).","journal-title":"Br. Dent. J."},{"key":"25347_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115411","volume":"137","author":"SR Cummings","year":"2020","unstructured":"Cummings, S. R., Santora, A. C., Black, D. M. & Russell, R. G. G. History of alendronate. Bone 137, 115411 (2020).","journal-title":"Bone"},{"key":"25347_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115244","volume":"134","author":"SE Papapoulos","year":"2020","unstructured":"Papapoulos, S. E. Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective. Bone 134, 115244 (2020).","journal-title":"Bone"},{"key":"25347_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2474-10-86","volume":"10","author":"DA Eekman","year":"2009","unstructured":"Eekman, D. A. et al. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet. Disord. 10, 86 (2009).","journal-title":"BMC Musculoskelet. Disord."},{"key":"25347_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coms.2014.01.009","volume":"26","author":"A Eid","year":"2014","unstructured":"Eid, A. & Atlas, J. The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. Oral. Maxillofac. Surg. Clin. N. Am. 26, 231\u2013237 (2014).","journal-title":"Oral. Maxillofac. Surg. Clin. N. Am."},{"key":"25347_CR6","doi-asserted-by":"crossref","unstructured":"Peng, J. et al. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database. Front. Pharmacol. 13 (2022).","DOI":"10.3389\/fphar.2022.1017391"},{"key":"25347_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127970","volume":"10","author":"J Kim","year":"2015","unstructured":"Kim, J. et al. Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: From a national health insurance claims database. PLoS\u00a0One 10, e0127970 (2015).","journal-title":"PLoS\u00a0One"},{"key":"25347_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40902-016-0099-4","volume":"39","author":"WS Choi","year":"2017","unstructured":"Choi, W. S., Lee, J. I., Yoon, H. J., Min, C. K. & Lee, S. H. Medication-related osteonecrosis of the jaw: A preliminary retrospective study of 130 patients with multiple myeloma. Maxillofac. Plast. Reconstr. Surg. 39, 1 (2017).","journal-title":"Maxillofac. Plast. Reconstr. Surg."},{"key":"25347_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral. Maxillofac. Surg. 61, 1115\u20131117 (2003).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"25347_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J. Oral. Maxillofac. Surg. 72, 1938\u20131956 (2014).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"25347_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda, T. et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J. Bone Miner. Metab. 35, 6\u201319 (2017).","journal-title":"J. Bone Miner. Metab."},{"key":"25347_CR12","volume":"12","author":"R Mhaskar","year":"2017","unstructured":"Mhaskar, R., Kumar, A., Miladinovic, B. & Djulbegovic, B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst. Rev. 12, cd003188 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"25347_CR13","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9202","volume":"8","author":"SS Lee","year":"2020","unstructured":"Lee, S. S., Kim, S. M., Kim, Y. S. & Lee, S. K. Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC. PeerJ 8, e9202 (2020).","journal-title":"PeerJ"},{"key":"25347_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03795","volume":"6","author":"C Ottesen","year":"2020","unstructured":"Ottesen, C., Schiodt, M. & Gotfredsen, K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review. Heliyon 6, e03795 (2020).","journal-title":"Heliyon"},{"key":"25347_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis, P. et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101, 23\u201330 (2017).","journal-title":"Maturitas"},{"key":"25347_CR16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0278-2391(09)00013-5","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J. Oral. Maxillofac. Surg. 67, 2\u201312 (2009).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"25347_CR17","first-page":"33","volume":"61","author":"DD Damm","year":"2013","unstructured":"Damm, D. D. & Jones, D. M. Bisphosphonate-related osteonecrosis of the jaws: A potential alternative to drug holidays. Gen. Dent. 61, 33\u201338 (2013).","journal-title":"Gen. Dent."},{"key":"25347_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2209\/tdcpublication.54.117","volume":"54","author":"T Nomura","year":"2013","unstructured":"Nomura, T. et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: A case series of 13 patients at our clinic. Bull. Tokyo Dent. Coll. 54, 117\u2013125 (2013).","journal-title":"Bull. Tokyo Dent. Coll."},{"key":"25347_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00784-017-2325-6","volume":"22","author":"L Ramaglia","year":"2018","unstructured":"Ramaglia, L. et al. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: A systematic review and meta-analysis of the drug suspension protocol. Clin. Oral. Investig. 22, 597\u2013615 (2018).","journal-title":"Clin. Oral. Investig."},{"key":"25347_CR20","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.4119","volume":"35","author":"S Otto","year":"2020","unstructured":"Otto, S. et al. A drug holiday reduces the frequency and severity of medication-related osteonecrosis of the jaw in a minipig model. J. Bone Miner. Res. 35, 2179\u20132192 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"25347_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jcms.2015.08.008","volume":"43","author":"M Zandi","year":"2015","unstructured":"Zandi, M., Dehghan, A., Ghadermazi, K., Malekzadeh, H. & Akbarzadeh, M. Perioperative discontinuation of intravenous bisphosphonate therapy reduces the incidence and severity of bisphosphonate-related osteonecrosis of the jaw: A randomized, controlled, prospective experimental study in rats. J. Craniomaxillofac. Surg. 43, 1823\u20131828 (2015).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"25347_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, e3000410 (2020).","journal-title":"PLoS Biol."},{"key":"25347_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/ilar.43.4.244","volume":"43","author":"MF Festing","year":"2002","unstructured":"Festing, M. F. & Altman, D. G. Guidelines for the design and statistical analysis of experiments using laboratory animals. Ilar J. 43, 244\u2013258 (2002).","journal-title":"Ilar J."},{"key":"25347_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0023677217738268","volume":"52","author":"MF Festing","year":"2018","unstructured":"Festing, M. F. On determining sample size in experiments involving laboratory animals. Lab. Anim. 52, 341\u2013350 (2018).","journal-title":"Lab. Anim."},{"key":"25347_CR25","first-page":"445","volume":"50","author":"DA Fitts","year":"2011","unstructured":"Fitts, D. A. Ethics and animal numbers: Informal analyses, uncertain sample sizes, inefficient replications, and type I errors. J. Am. Assoc. Lab. Anim. Sci. 50, 445\u2013453 (2011).","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"25347_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 31: Tests for correlation and regression analyses. Behav. Res. Methods 41, 1149\u20131160 (2009).","journal-title":"Behav. Res. Methods"},{"key":"25347_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/clr.12502","volume":"27","author":"CL Li","year":"2016","unstructured":"Li, C. L. et al. Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats. Clin. Oral. Implants Res. 27, 1\u20136 (2016).","journal-title":"Clin. Oral. Implants Res."},{"key":"25347_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4097\/kja.20662","volume":"74","author":"MJ Ko","year":"2021","unstructured":"Ko, M. J. & Lim, C. Y. General considerations for sample size estimation in animal study. Korean J. Anesthesiol. 74, 23\u201329 (2021).","journal-title":"Korean J. Anesthesiol."},{"key":"25347_CR29","first-page":"624","volume":"4","author":"P Sengupta","year":"2013","unstructured":"Sengupta, P. The laboratory rat: Relating its age with human\u2019s. Int. J. Prev. Med. 4, 624\u2013630 (2013).","journal-title":"Int. J. Prev. Med."},{"key":"25347_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","volume":"9","author":"N Fedchenko","year":"2014","unstructured":"Fedchenko, N. & Reifenrath, J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue\u2014A review. Diagn Pathol 9, 221 (2014).","journal-title":"Diagn Pathol"},{"key":"25347_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3070","volume":"11","author":"C Shi","year":"2011","unstructured":"Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11, 762\u2013774 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"25347_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/laban0707-25","volume":"36","author":"GA Coria-Avila","year":"2007","unstructured":"Coria-Avila, G. A., Gavrila, A. M., M\u00e9nard, S., Ismail, N. & Pfaus, J. G. Cecum location in rats and the implications for intraperitoneal injections. Lab. Anim. 36, 25\u201330 (2007).","journal-title":"Lab. Anim."},{"key":"25347_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jcms.2012.11.023","volume":"41","author":"T Hasegawa","year":"2013","unstructured":"Hasegawa, T. et al. The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. J. Craniomaxillofac. Surg. 41, 558\u2013563 (2013).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"25347_CR34","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx, R. E., Cillo, J. E. Jr. & Ulloa, J. J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral. Maxillofac. Surg. 65, 2397\u20132410 (2007).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"25347_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras, A. G., Holland, S. D. & Gertz, B. J. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36, 315\u2013328 (1999).","journal-title":"Clin. Pharmacokinet."},{"key":"25347_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1600-0714.2010.00927.x","volume":"39","author":"P L\u00f3pez-Jornet","year":"2010","unstructured":"L\u00f3pez-Jornet, P., Camacho-Alonso, F., Molina-Mi\u00f1ano, F., G\u00f3mez-Garc\u00eda, F. & Vicente-Ortega, V. An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague\u2013Dawley rats. J. Oral. Pathol. Med. 39, 697\u2013702 (2010).","journal-title":"J. Oral. Pathol. Med."},{"key":"25347_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/ijos.2017.11","volume":"9","author":"M Chatterjee","year":"2017","unstructured":"Chatterjee, M. et al. A robust methodology for the quantitative assessment of the rat jawbone microstructure. Int. J. Oral. Sci. 9, 87\u201394 (2017).","journal-title":"Int. J. Oral. Sci."},{"key":"25347_CR38","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/bcp.13867","volume":"85","author":"S Cremers","year":"2019","unstructured":"Cremers, S., Drake, M. T., Ebetino, F. H., Bilezikian, J. P. & Russell, R. G. G. Pharmacology of bisphosphonates. Br. J. Clin. Pharmacol. 85, 1052\u20131062 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"25347_CR39","doi-asserted-by":"publisher","first-page":"1271492","DOI":"10.1155\/2019\/1271492","volume":"2019","author":"NJ Rao","year":"2019","unstructured":"Rao, N. J., Yu, R. Q., Wang, J. Y., Helm, A. & Zheng, L. W. Effect of periapical diseases in development of MRONJ in immunocompromised mouse model. Biomed. Res. Int. 2019, 1271492 (2019).","journal-title":"Biomed. Res. Int."},{"key":"25347_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.archoralbio.2017.06.002","volume":"82","author":"JLP Vilarinho","year":"2017","unstructured":"Vilarinho, J. L. P. et al. Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: A longitudinal in vivo study. Arch. Oral. Biol. 82, 79\u201385 (2017).","journal-title":"Arch. Oral. Biol."},{"key":"25347_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jcms.2021.02.018","volume":"49","author":"R Schoenhof","year":"2021","unstructured":"Schoenhof, R. et al. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis. J. Craniomaxillofac. Surg. 49, 508\u2013517 (2021).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"25347_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173228","volume":"12","author":"M Berli","year":"2017","unstructured":"Berli, M. et al. Localized tissue mineralization regulated by bone remodelling: A computational approach. PLoS\u00a0One 12, e0173228 (2017).","journal-title":"PLoS\u00a0One"},{"key":"25347_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bone.2014.11.016","volume":"72","author":"C Lerebours","year":"2015","unstructured":"Lerebours, C., Thomas, C. D., Clement, J. G., Buenzli, P. R. & Pivonka, P. The relationship between porosity and specific surface in human cortical bone is subject specific. Bone 72, 109\u2013117 (2015).","journal-title":"Bone"},{"key":"25347_CR44","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.oooo.2016.09.225","volume":"123","author":"SM Kim","year":"2017","unstructured":"Kim, S. M., Eo, M. Y., Kim, Y. S. & Lee, S. K. Histochemical observation of bony reversal lines in bisphosphonate-related osteonecrosis of the jaw. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 123, 220\u2013228 (2017).","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."},{"key":"25347_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","volume":"18","author":"A Sauty","year":"1996","unstructured":"Sauty, A. et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18, 133\u2013139 (1996).","journal-title":"Bone"},{"key":"25347_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ijos.2014.46","volume":"6","author":"S Pushalkar","year":"2014","unstructured":"Pushalkar, S. et al. Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw. Int. J. Oral. Sci. 6, 219\u2013226 (2014).","journal-title":"Int. J. Oral. Sci."},{"key":"25347_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bonr.2018.03.003","volume":"8","author":"EL George","year":"2018","unstructured":"George, E. L., Lin, Y. L. & Saunders, M. M. Bisphosphonate-related osteonecrosis of the jaw: A mechanobiology perspective. Bone Rep. 8, 104\u2013109 (2018).","journal-title":"Bone Rep."},{"key":"25347_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/odi.12513","volume":"22","author":"PG de Barros Silva","year":"2016","unstructured":"de Barros Silva, P. G. et al. Immune cellular profile of bisphosphonate-related osteonecrosis of the jaw. Oral. Dis. 22, 649\u2013657 (2016).","journal-title":"Oral. Dis."},{"key":"25347_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/iej.13206","volume":"53","author":"RAB Silva","year":"2020","unstructured":"Silva, R. A. B. et al. Alendronate inhibits osteocyte apoptosis and inflammation via IL-6, inhibiting bone resorption in periapical lesions of ovariectomized rats. Int. Endod. J. 53, 84\u201396 (2020).","journal-title":"Int. Endod. J."},{"key":"25347_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0928-0987(98)00065-7","volume":"8","author":"N Makkonen","year":"1999","unstructured":"Makkonen, N. et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: The role of a bisphosphonate metabolite. Eur. J. Pharm. Sci. 8, 109\u2013118 (1999).","journal-title":"Eur. J. Pharm. Sci."},{"key":"25347_CR51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12967-019-2129-3","volume":"17","author":"KH Lee","year":"2019","unstructured":"Lee, K. H. et al. Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: A case control study. J. Transl. Med. 17, 381 (2019).","journal-title":"J. Transl. Med."},{"key":"25347_CR52","doi-asserted-by":"publisher","first-page":"18896","DOI":"10.1038\/s41598-019-55383-5","volume":"9","author":"T Tamari","year":"2019","unstructured":"Tamari, T. et al. Endothelial progenitor cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy. Sci. Rep. 9, 18896 (2019).","journal-title":"Sci. Rep."},{"key":"25347_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/1874325000903010083","volume":"3","author":"KD Evans","year":"2009","unstructured":"Evans, K. D. & Oberbauer, A. M. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop. J. 3, 83\u201388 (2009).","journal-title":"Open Orthop. J."},{"key":"25347_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.tripleo.2011.02.028","volume":"112","author":"F Wehrhan","year":"2011","unstructured":"Wehrhan, F. et al. Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 112, 216\u2013221 (2011).","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod."},{"key":"25347_CR55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12967-017-1230-8","volume":"15","author":"C Gross","year":"2017","unstructured":"Gross, C. et al. Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: A comparison with osteoradionecrosis and osteomyelitis. J. Transl. Med. 15, 128 (2017).","journal-title":"J. Transl. Med."},{"key":"25347_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214173","volume":"14","author":"CC Biguetti","year":"2019","unstructured":"Biguetti, C. C. et al. Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization. PLoS ONE 14, e0214173 (2019).","journal-title":"PLoS ONE"},{"key":"25347_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.7150\/ijms.22627","volume":"15","author":"FJ Manzano-Moreno","year":"2018","unstructured":"Manzano-Moreno, F. J. et al. Bisphosphonate modulation of the gene expression of different markers involved in osteoblast physiology: Possible implications in bisphosphonate-related osteonecrosis of the jaw. Int. J. Med. Sci. 15, 359\u2013367 (2018).","journal-title":"Int. J. Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25347-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T12:16:20Z","timestamp":1670847380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25347-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"assertion":[{"value":"13 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21449"}}